| Literature DB >> 22254140 |
Daniel S Tsze1, Jonathan H Valente.
Abstract
Stroke is relatively rare in children, but can lead to significant morbidity and mortality. Understanding that children with strokes present differently than adults and often present with unique risk factors will optimize outcomes in children. Despite an increased incidence of pediatric stroke, there is often a delay in diagnosis, and cases may still remain under- or misdiagnosed. Clinical presentation will vary based on the child's age, and children will have risk factors for stroke that are less common than in adults. Management strategies in children are extrapolated primarily from adult studies, but with different considerations regarding short-term anticoagulation and guarded recommendations regarding thrombolytics. Although most recommendations for management are extrapolated from adult populations, they still remain useful, in conjunction with pediatric-specific considerations.Entities:
Year: 2011 PMID: 22254140 PMCID: PMC3255104 DOI: 10.1155/2011/734506
Source DB: PubMed Journal: Emerg Med Int ISSN: 2090-2840 Impact factor: 1.112
Clinical presentation of pediatric ischemic and hemorrhagic strokes.
| Ischemic | Hemorrhagic | |||
|---|---|---|---|---|
| Earley et al. 1998 [ | DeVeber et al. 2000 [ | Earley et al. 1998 [ | Meyer-Heim and Boltshauser et al. 2003 [ | |
|
| ||||
| Hemiparesis or focal CNS deficit | 94% | 51% | 21% | 16% |
| Change in mental status | 28% | 88% | 52% | |
| Headache | 22% | 59% | 76% | |
| Seizure | 16% | 48% | 29% | 28% |
| Speech disorder, incl. aphasia | 17% | 8% | ||
| Vomiting | 48% | |||
| Nausea | 20% | |||
| Somnolence | 12% | |||
| Visual impairment | 12% | |||
| Neck pain | 8% | |||
| Fever/prodrome | 35–40% | 35–40% | ||
Laboratory and diagnostic testing considerations for the acute pediatric stroke patient.
| Additional laboratory tests to consider | Additional tests to consider |
|---|---|
| Liver function | Brain MRI |
| ESR | MRA |
| CRP | (i) Intracranial vessels |
| Pregnancy | (ii) Extracranial great vessels (neck) |
| ANA | MRV |
| Lupus anticoagulant | Diffusion weighted imaging (DWI) |
| Anticardiolipin antibody | CT angiogram |
| Beta-2 glycoprotein-1 antibody | (i) Intracranial vessels |
| Activated protein C resistance | (ii) Extracranial great vessels (neck) |
| Factor V Leiden mutation | Contrast transthoracic echo (TTE) |
| Protein S/C function | Cerebral angiogram |
| Antithrombin III | Contrast transesophageal echo (TEE) |
| Prothrombin gene mutation | Electroencephalogram (EEG) |
| Homocysteine level | Lumbar puncture |
| Methyltetrahydrofolate reductase allele (MTHFR) | Holter monitoring |
| Fibrinogen disorder | Transcranial doppler |
| Plasminogen activator inhibitor disorder | |
| Factor VII/VIII elevation | |
| Factor XII deficiency | |
| Plasma amino acids/urine amino and organic acids | |
| Serum and CSF lactate/pyruvate | |
| Hemoglobin electrophoresis | |
| Triglycerides/cholesterol | |
| Lipoprotein (a) | |
| Miscellaneous bacterial, fungal, spirochetal, parasitic, | |
| viral, and rickettsial tests (i.e., Lyme, PPD, VDRL) | |
| Serum and CSF varicella titers | |
| HIV titers |
Adapted from Younkin [23] and Deveber [92].
Protocol for using LMWH in children.
| Preparation | Initial treatment dose | Initial prophylactic dose |
|---|---|---|
| Reviparin, body weight-dependent dose, units/kg per 12 h | ||
| <5 kg | 150 | 50 |
| >5 kg | 100 | 30 |
|
| ||
| Enoxaparin, age-dependent dose, mg/kg per 12 h | ||
| <2 months old | 1.5 | 0.75 |
| >2 months old | 1.0 | 0.5 |
| Dalteparin, all-age pediatric dose, units/kg per 24 h | 129 ± 43 | 95 ± 52 |
|
| ||
| Tinzaparin, age-dependent dose, units/kg | ||
| 0 to 2 months old | 275 | |
| 2 to 12 months old | 250 | |
| 1 to 5 years old | 240 | |
| 5 to 10 years old | 200 | |
| 10 to 16 years old | 275 | |
Adapted from Roach et al. [88].
Protocol for systemic heparin administration and adjustment in children.
| Stage | aPTT (sec) | Dose (units/kg) | Hold (min) | Rate change (%) | Repeat aPTT |
|---|---|---|---|---|---|
| (I) Loading dose | 75 IV over 10 min | ||||
| (II) Initial maintenance dose | |||||
| Infants < 1 yo | 28/h | ||||
| Children > 1 yo | 20/h | ||||
| (III) Adjustment | <50 | 50 | 0 | 10 | 4 h |
| 50–59 | 0 | 0 | 10 | 4 h | |
| 60–85 | 0 | 0 | 0 | Next day | |
| 86–95 | 0 | 0 | −10 | 4 h | |
| 96–120 | 0 | 30 | −10 | 4 h | |
| >120 | 0 | 60 | −15 | 4 h | |
| (IV) Obtain blood for aPTT 4 h after heparin load and 4 h after every infusion rate change | |||||
| (V) When apt values are in therapeutic range, perform daily CBC and apt measurement | |||||
Adapted from Roach et al. [88]